PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized ...

Semaglutide 2.4 mg could prevent nearly 2 million major cardiac events and over 1 million deaths in eligible patients. Uptake of semaglutide remains low due to cost, supply issues, and payer ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...

Semaglutide in particular, whose brand names include Wegovy and Ozempic, showed promise in cutting the risk of conditions that impair memory and thought processes, according to researchers ...

Patients who received preoperative semaglutide had lower postoperative total weight loss at 12 months compared with controls. Median HbA1c levels and diabetes remission at 1 year were similar ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

As the use of semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, continues to rise among people with and without diabetes, the safety profile of this medication requires closer scrutiny.

Another weight loss jag, Wegovy (semaglutide) is also available on the NHS, again only through specialist weight management services for those who meet similar specific eligibility criteria.

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...